Top

Published in:

01-04-2013

ARB and Cardioprotection

Authors: Hiroshi Akazawa, Chizuru Yabumoto, Masamichi Yano, Yoko Kudo-Sakamoto, Issei Komuro

Published in: Cardiovascular Drugs and Therapy | Issue 2/2013

Abstract

A growing body of evidence has suggested that the use of angiotensin II (Ang II) type 1 (AT₁) receptor blockers (ARBs) leads to a significant decrease in mortality and morbidity in patients with congestive heart failure. The AT₁ receptor is a seven-transmembrane G protein-coupled receptor, and is involved in regulating the physiological and pathological process of the cardiovascular system. Systemically and locally generated Ang II has agonistic action on AT₁ receptor. However, recent in vitro studies have demonstrated that AT₁ receptor is structurally flexible and instable, and has significant and varying levels of spontaneous activity in an Ang II-independent manner. Furthermore, mechanical stress activates AT₁ receptor by inducing conformational switch without the involvement of Ang II. Experimental studies have demonstrated that Ang II-independent activation of AT₁ receptor is profoundly relevant to the pathogenesis of cardiac remodeling in vivo, and that these agonist-independent activities of AT₁ receptor can be inhibited by inverse agonists, but not by neutral antagonists. Therefore, inverse agonist activity emerges as an important pharmacological parameter that contributes to cardioprotective effects of ARBs through inhibiting both Ang II-dependent and -independent activation of AT₁ receptor.

Re RN. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2004;1:42–7.PubMed

Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747–803.PubMedCrossRef

Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205–51.PubMed

Gether U, Kobilka BK. G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem. 1998;273:17979–82.PubMedCrossRef

Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev. 2000;21:90–113.PubMedCrossRef

Miura S, Saku K, Karnik SS. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res. 2003;26:937–43.PubMedCrossRef

Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002;1:621–36.PubMedCrossRef

Dell’italia LJ. Translational success stories: angiotensin receptor 1 antagonists in heart failure. Circ Res. 2011;109:437–52.PubMedCrossRef

Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.PubMedCrossRef

10.

Yasuda N, Miura S, Akazawa H, Tanaka T, Qin Y, Kiya Y, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep. 2008;9:179–86.PubMedCrossRef

11.

Qin Y, Yasuda N, Akazawa H, Ito K, Kudo Y, Liao CH, et al. Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation. Hypertens Res. 2009;32:875–83.PubMedCrossRef

12.

Akazawa H, Yasuda N, Komuro I. Mechanisms and functions of agonist-independent activation in the angiotensin II type 1 receptor. Mol Cell Endocrinol. 2009;302:140–7.PubMedCrossRef

13.

Yasuda N, Akazawa H, Ito K, Shimizu I, Kudo-Sakamoto Y, Yabumoto C, et al. Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice. Hypertension. 2012;59:627–33.PubMedCrossRef

14.

Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol. 2004;6:499–506.PubMedCrossRef

15.

Mederos y Schnitzler M, Storch U, Meibers S, Nurwakagari P, Breit A, Essin K, et al. Gq-coupled receptors as mechanosensors mediating myogenic vasoconstriction. EMBO J. 2008;27:3092–103.PubMedCrossRef

16.

Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal. 2010;3:ra46.PubMedCrossRef

17.

Strange PG. Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci. 2002;23:89–95.PubMedCrossRef

18.

Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol. 2003;64:1271–6.PubMedCrossRef

19.

Bond RA, Ijzerman AP. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci. 2006;27:92–6.PubMedCrossRef

20.

Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470–9.PubMedCrossRef

21.

Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor. Am J Hypertens. 1992;5:276–80.PubMed

22.

Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK, Dzau VJ. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci U S A. 1997;94:6391–6.PubMedCrossRef

23.

Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A. 2000;97:931–6.PubMedCrossRef

24.

Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–6.PubMedCrossRef

25.

Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491–8.PubMedCrossRef

26.

Ogihara T, Fujimoto A, Nakao K, Saruta T. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther. 2008;6:1195–201.PubMedCrossRef

27.

Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11–34.PubMed

28.

Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20:953–70.PubMedCrossRef

29.

Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, et al. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res. 1995;77:258–65.PubMedCrossRef

30.

Zou Y, Komuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I, et al. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem. 1996;271:33592–7.PubMedCrossRef

31.

Kudoh S, Komuro I, Mizuno T, Yamazaki T, Zou Y, Shiojima I, et al. Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res. 1997;80:139–46.PubMedCrossRef

32.

Nishida M, Tanabe S, Maruyama Y, Mangmool S, Urayama K, Nagamatsu Y, et al. G alpha 12/13- and reactive oxygen species-dependent activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J Biol Chem. 2005;280:18434–41.PubMedCrossRef

33.

Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res. 2002;91:776–81.PubMedCrossRef

34.

Hunyady L, Turu G. The role of the AT1 angiotensin receptor in cardiac hypertrophy: angiotensin II receptor or stretch sensor? Trends Endocrinol Metab. 2004;15:405–8.PubMed

35.

Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem. 2006;281:19288–95.PubMedCrossRef

36.

Billet S, Bardin S, Verp S, Baudrie V, Michaud A, Conchon S, et al. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest. 2007;117:1914–25.PubMedCrossRef

37.

Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 1993;73:439–47.PubMedCrossRef

38.

Fujii N, Tanaka M, Ohnishi J, Yukawa K, Takimoto E, Shimada S, et al. Alterations of angiotensin II receptor contents in hypertrophied hearts. Biochem Biophys Res Commun. 1995;212:326–33.PubMedCrossRef

39.

Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 1995;95:46–54.PubMedCrossRef

40.

Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu Rev Physiol. 1993;55:55–75.PubMedCrossRef

41.

Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997;59:551–71.PubMedCrossRef

42.

Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343–9.PubMedCrossRef

43.

Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977–84.PubMedCrossRef

44.

Yamano Y, Ohyama K, Chaki S, Guo DF, Inagami T. Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis. Biochem Biophys Res Commun. 1992;187:1426–31.PubMedCrossRef

45.

Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, et al. Angiotensinogen-deficient mice with hypotension. J Biol Chem. 1994;269:31334–7.PubMed

46.

Miura S, Kiya Y, Kanazawa T, Imaizumi S, Fujino M, Matsuo Y, et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol. 2008;22:139–46.PubMedCrossRef

47.

Fujino M, Miura S, Kiya Y, Tominaga Y, Matsuo Y, Karnik SS, et al. A small difference in the molecular structure of angiotensin II receptor blockers induces AT receptor-dependent and -independent beneficial effects. Hypertens Res. 2010;33:1044–52.

Title: ARB and Cardioprotection
Authors: Hiroshi Akazawa
Chizuru Yabumoto
Masamichi Yano
Yoko Kudo-Sakamoto
Issei Komuro
Publication date: 01-04-2013
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue 2/2013
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-012-6392-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

ARB and Cardioprotection

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

It is Time to Reconsider the Cardiovascular Protection Afforded by RAAS Blockade - Overview of RAAS Systems

Two Classes of Anti-Platelet Drugs Reduce Anatomical Infarct Size in Monkey Hearts

Asialoerythropoietin Exerts Stronger Angiogenic Activity than Erythropoietin Via its Binding Affinity to Tissue

Liposomal Amiodarone Augments Anti-arrhythmic Effects and Reduces Hemodynamic Adverse Effects in an Ischemia/Reperfusion Rat Model

Cardioprotection—Time to Take Into Account Clinical Complexity: The Case of Antiplatelet Agents

RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page